Verona Eyes New Milestones Ahead, Will The Stock Get A Boost?
After a year of remarkable achievements, Verona Pharma plc (VRNA) looks to make 2023 even more momentous.
Verona Pharma is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs.
The lead drug candidate is Ensifentrine, which combines bronchodilator and anti-inflammatory properties in one compound, with the potential to be an effective treatment for chronic obstructive pulmonary disease and other respiratory diseases, including asthma and cystic fibrosis.
Ensifentrine, in nebulized formulation, has been studied in a phase III program for chronic obstructive pulmonary disease maintenance treatment, dubbed ENHANCE, comprising of two trials - ENHANCE-1 and ENHANCE-2.